#BEGIN_DRUGCARD DB02643

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C17H38NO3S

# Chemical_IUPAC_Name:
dodecyldimethyl(3-sulfopropyl)azanium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
N-Dodecyl-N,N-Dimethyl-3-Ammonio-1-Propanesulfonate

# HET_ID:
C15

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C17H37NO3S/c1-4-5-6-7-8-9-10-11-12-13-15-18(2,3)16-14-17-22(19,20)21/h4-17H2,1-3H3/p+1

# InChI_Key:
InChIKey=IZWSFJTYBVKZNK-UHFFFAOYSA-O

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2643

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
336.554

# Molecular_Weight_Mono:
336.257239777

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1X9P

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0.35

# Predicted_LogS:
-6.3

# Predicted_Water_Solubility:
1.89e-04 g/l

# Primary_Accession_No:
DB02643

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
84704

# PubChem_Substance_ID:
46505495

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00799

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCCCCCCCCCCC[N+](C)(C)CCCS(O)(=O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:20 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
J01917

# Drug_Target_1_GenBank_ID_Protein:
209827

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
PIII

# Drug_Target_1_Gene_Sequence:
>1716 bp
ATGCAGCGCGCGGCGATGTATGAGGAAGGTCCTCCTCCCTCCTACGAGAGCGTGGTGAGC
GCGGCGCCAGTGGCGGCGGCGCTGGGTTCCCCCTTCGATGCTCCCCTGGACCCGCCGTTT
GTGCCTCCGCGGTACCTGCGGCCTACCGGGGGGAGAAACAGCATCCGTTACTCTGAGTTG
GCACCCCTATTCGACACCACCCGTGTGTACCTTGTGGACAACAAGTCAACGGATGTGGCA
TCCCTGAACTACCAGAACGACCACAGCAACTTTCTAACCACGGTCATTCAAAACAATGAC
TACAGCCCGGGGGAGGCAAGCACACAGACCATCAATCTTGACGACCGTTCGCACTGGGGC
GGCGACCTGAAAACCATCCTGCATACCAACATGCCAAATGTGAACGAGTTCATGTTTACC
AATAAGTTTAAGGCGCGGGTGATGGTGTCGCGCTCGCTTACTAAGGACAAACAGGTGGAG
CTGAAATATGAGTGGGTGGAGTTCACGCTGCCCGAGGGCAACTACTCCGAGACCATGACC
ATAGACCTTATGAACAACGCGATCGTGGAGCACTACTTGAAAGTGGGCAGGCAGAACGGG
GTTCTGGAAAGCGACATCGGGGTAAAGTTTGACACCCGCAACTTCAGACTGGGGTTTGAC
CCAGTCACTGGTCTTGTCATGCCTGGGGTATATACAAACGAAGCCTTCCATCCAGACATC
ATTTTGCTGCCAGGATGCGGGGTGGACTTCACCCACAGCCGCCTGAGCAACTTGTTGGGC
ATCCGCAAGCGGCAACCCTTCCAGGAGGGCTTTAGGATCACCTACGATGACCTGGAGGGT
GGTAACATTCCCGCACTGTTGGATGTGGACGCCTACCAGGCAAGCTTAAAAGATGACACC
GAACAGGGCGGGGATGGCGCAGGCGGCGGCAACAACAGTGGCAGCGGCGCGGAAGAGAAC
TCCAACGCGGCAGCCGCGGCAATGCAGCCGGTGGAGGACATGAACGATCATGCCATTCGC
GGCGACACCTTTGCCACACGGGCGGAGGAGAAGCGCGCTGAGGCCGAGGCAGCGGCAGAA
GCTGCCGCCCCCGCTGCGCAACCCGAGGTCGAGAAGCCTCAGAAGAAACCGGTGATCAAA
CCCCTGACAGAGGACAGCAAGAAACGCAGTTACAACCTAATAAGCAATGACAGCACCTTC
ACCCAGTACCGCAGCTGGTACCTTGCATACAACTACGGCGACCCTCAGACCGGGATCCGC
TCATGGACCCTCCTTTGCACTCCTGACGTAACCTGCGGCTCGGAGCAGGTCTACTGGTCG
TTGCCAGACATGATGCAAGACCCCGTGACCTTCCGCTCCACGAGCCAGATCAGCAACTTT
CCGGTGGTGGGCGCCGAGCTGTTGCCCGTGCACTCCAAGAGCTTCTACAACGACCAGGCC
GTCTACTCCCAGCTCATCCGCCAGTTTACCTCTCTGACCCACGTGTTCAATCGCTTTCCC
GAGAACCAGATTTTGGCGCGCCCGCCAGCCCCCACCATCACCACCGTCAGTGAAAACGTT
CCTGCTCTCACAGATCACGGGACGCTACCGCTGCGCAACAGCATCGGAGGAGTCCAGCGA
GTGACCATTACTGACGCCAGACGCCGCACCTGCCCCTACGTTTACAAGGCCCTGGGCATA
GTCTCGCCGCGCGTCCTATCGAGCCGCACTTTTTGA

# Drug_Target_1_General_Function:
Involved in structural molecule activity

# Drug_Target_1_General_References:
12450395	Galinier R, Gout E, Lortat-Jacob H, Wood J, Chroboczek J: Adenovirus protein involved in virus internalization recruits ubiquitin-protein ligases. Biochemistry. 2002 Dec 3;41(48):14299-305.
6094534	Alestrom P, Akusjarvi G, Lager M, Yeh-kai L, Pettersson U: Genes encoding the core proteins of adenovirus type 2. J Biol Chem. 1984 Nov 25;259(22):13980-5.
6334081	Roberts RJ, O'Neill KE, Yen CT: DNA sequences from the adenovirus 2 genome. J Biol Chem. 1984 Nov 25;259(22):13968-75.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2864

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
63255

# Drug_Target_1_Name:
Penton protein

# Drug_Target_1_Number_of_Residues:
571

# Drug_Target_1_PDB_ID:
1X9T

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01686	Adeno_Penton_B

# Drug_Target_1_Protein_Sequence:
>Penton protein
MQRAAMYEEGPPPSYESVVSAAPVAAALGSPFDAPLDPPFVPPRYLRPTGGRNSIRYSEL
APLFDTTRVYLVDNKSTDVASLNYQNDHSNFLTTVIQNNDYSPGEASTQTINLDDRSHWG
GDLKTILHTNMPNVNEFMFTNKFKARVMVSRSLTKDKQVELKYEWVEFTLPEGNYSETMT
IDLMNNAIVEHYLKVGRQNGVLESDIGVKFDTRNFRLGFDPVTGLVMPGVYTNEAFHPDI
ILLPGCGVDFTHSRLSNLLGIRKRQPFQEGFRITYDDLEGGNIPALLDVDAYQASLKDDT
EQGGDGAGGGNNSGSGAEENSNAAAAAMQPVEDMNDHAIRGDTFATRAEEKRAEAEAAAE
AAAPAAQPEVEKPQKKPVIKPLTEDSKKRSYNLISNDSTFTQYRSWYLAYNYGDPQTGIR
SWTLLCTPDVTCGSEQVYWSLPDMMQDPVTFRSTSQISNFPVVGAELLPVHSKSFYNDQA
VYSQLIRQFTSLTHVFNRFPENQILARPPAPTITTVSENVPALTDHGTLPLRNSIGGVQR
VTITDARRRTCPYVYKALGIVSPRVLSSRTF

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P03276

# Drug_Target_1_SwissProt_Name:
PEN3_ADE02

# Drug_Target_1_Synonyms:
Penton base protein
Virion component III
pIII

# Drug_Target_1_Theoretical_pI:
5.07

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Secreted

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
IGF1

# Drug_Target_2_GenBank_ID_Gene:
M14155

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
IGF1

# Drug_Target_2_Gene_Sequence:
>588 bp
ATGGGAAAAATCAGCAGTCTTCCAACCCAATTATTTAAGTGCTGCTTTTGTGATTTCTTG
AAGGTGAAGATGCACACCATGTCCTCCTCGCATCTCTTCTACCTGGCGCTGTGCCTGCTC
ACCTTCACCAGCTCTGCCACGGCTGGACCGGAGACGCTCTGCGGGGCTGAGCTGGTGGAT
GCTCTTCAGTTCGTGTGTGGAGACAGGGGCTTTTATTTCAACAAGCCCACAGGGTATGGC
TCCAGCAGTCGGAGGGCGCCTCAGACAGGCATCGTGGATGAGTGCTGCTTCCGGAGCTGT
GATCTAAGGAGGCTGGAGATGTATTGCGCACCCCTCAAGCCTGCCAAGTCAGCTCGCTCT
GTCCGTGCCCAGCGCCACACCGACATGCCCAAGACCCAGAAGTATCAGCCCCCATCTACC
AACAAGAACACGAAGTCTCAGAGAAGGAAAGGTTGGCCAAAGACACATCCAGGAGGGGAA
CAGAAGGAGGGGACAGAAGCAAGTCTGCAGATCAGAGGAAAGAAGAAAGAGCAGAGGAGG
GAGATTGGAAGTAGAAATGCTGAATGCAGAGGCAAAAAAGGAAAATGA

# Drug_Target_2_General_Function:
Involved in prothoracicotrophic hormone activity

# Drug_Target_2_General_References:
1319992	Sato A, Nishimura S, Ohkubo T, Kyogoku Y, Koyama S, Kobayashi M, Yasuda T, Kobayashi Y: 1H-NMR assignment and secondary structure of human insulin-like growth factor-I (IGF-I) in solution. J Biochem. 1992 Apr;111(4):529-36.
2036417	Cooke RM, Harvey TS, Campbell ID: Solution structure of human insulin-like growth factor 1: a nuclear magnetic resonance and restrained molecular dynamics study. Biochemistry. 1991 Jun 4;30(22):5484-91.
2937782	Rotwein P, Pollock KM, Didier DK, Krivi GG: Organization and sequence of the human insulin-like growth factor I gene. Alternative RNA processing produces two insulin-like growth factor I precursor peptides. J Biol Chem. 1986 Apr 15;261(11):4828-32.
3002851	de Pagter-Holthuizen P, van Schaik FM, Verduijn GM, van Ommen GJ, Bouma BN, Jansen M, Sussenbach JS: Organization of the human genes for insulin-like growth factors I and II. FEBS Lett. 1986 Jan 20;195(1-2):179-84.
3455760	Rotwein P: Two insulin-like growth factor I messenger RNAs are expressed in human liver. Proc Natl Acad Sci U S A. 1986 Jan;83(1):77-81.
6189745	Blundell TL, Bedarkar S, Humbel RE: Tertiary structures, receptor binding, and antigenicity of insulinlike growth factors. Fed Proc. 1983 Jun;42(9):2592-7.
632300	Rinderknecht E, Humbel RE: The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem. 1978 Apr 25;253(8):2769-76.
6382022	Dull TJ, Gray A, Hayflick JS, Ullrich A: Insulin-like growth factor II precursor gene organization in relation to insulin gene family. Nature. 1984 Aug 30-Sep 5;310(5980):777-81.
8495408	Sandberg-Nordqvist AC, Stahlbom PA, Reinecke M, Collins VP, von Holst H, Sara V: Characterization of insulin-like growth factor 1 in human primary brain tumors. Cancer Res. 1993 Jun 1;53(11):2475-8.
8857020	Woods KA, Camacho-Hubner C, Savage MO, Clark AJ: Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med. 1996 Oct 31;335(18):1363-7.

# Drug_Target_2_HGNC_ID:
HGNC:5464

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
5841

# Drug_Target_2_Locus:
12q22-q23

# Drug_Target_2_Molecular_Weight:
21841

# Drug_Target_2_Name:
Insulin-like growth factor IB

# Drug_Target_2_Number_of_Residues:
195

# Drug_Target_2_PDB_ID:
1WQJ

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00049	Insulin

# Drug_Target_2_Protein_Sequence:
>Insulin-like growth factor IB
MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVD
ALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARS
VRAQRHTDMPKTQKYQPPSTNKNTKSQRRKGWPKTHPGGEQKEGTEASLQIRGKKKEQRR
EIGSRNAECRGKKGK

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-21

# Drug_Target_2_Specific_Function:
The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity

# Drug_Target_2_SwissProt_ID:
P05019

# Drug_Target_2_SwissProt_Name:
IGF1_HUMAN

# Drug_Target_2_Synonyms:
IGF-IB
Insulin-like growth factor IB precursor
MGF
Mechano growth factor
Somatomedin-C

# Drug_Target_2_Theoretical_pI:
10.32

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Mitochondrion

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
MAOB

# Drug_Target_3_GenBank_ID_Gene:
S62734

# Drug_Target_3_GenBank_ID_Protein:
398415

# Drug_Target_3_GeneCard_ID:
MAOB

# Drug_Target_3_Gene_Name:
MAOB

# Drug_Target_3_Gene_Sequence:
>1560 bp
ATGAGCAACAAATGCGACGTGGTCGTGGTGGGGGGCGGCATCTCAGGTATGGCAGCAGCC
AAACTTCTGCATGACTCTGGACTGAATGTGGTTGTTCTGGAAGCCCGGGACCGTGTGGGA
GGCAGGACTTACACTCTTAGGAACCAAAAGGTTAAATATGTGGACCTTGGAGGATCCTAT
GTTGGACCAACCCAGAATCGTATCTTGAGATTAGCCAAGGAGCTAGGATTGGAGACCTAC
AAAGTGAATGAGGTTGAGCGTCTGATCCACCATGTAAAGGGCAAATCATACCCCTTCAGG
GGGCCATTCCCACCTGTATGGAATCCAATTACCTACTTAGATCATAACAACTTTTGGAGG
ACAATGGATGACATGGGGCGAGAGATTCCGAGTGATGCCCCATGGAAGGCTCCCCTTGCA
GAAGAGTGGGACAACATGACAATGAAGGAGCTACTGGACAAGCTCTGCTGGACTGAATCT
GCAAAGCAGCTTGCCACTCTCTTTGTGAACCTGTGTGTCACTGCAGAGACCCATGAGGTC
TCTGCTCTCTGGTTCCTGTGGTATGTGAAGCAGTGTGGAGGCACAACAAGAATCATCTCG
ACAACAAATGGAGGACAGGAGAGGAAATTTGTGGGCGGATCTGGTCAAGTGAGTGAGCGG
ATAATGGACCTCCTTGGAGACCGAGTGAAGCTGGAGAGGCCTGTGATCTACATTGACCAG
ACAAGAGAAAATGTCCTTGTGGAGACCCTAAACCATGAGATGTATGAGGCTAAATATGTG
ATTAGTGCTATTCCTCCTACTCTGGGCATGAAGATTCACTTCAATCCCCCTCTGCCAATG
ATGAGAAACCAGATGATCACTCGTGTGCCTTTGGGTTCAGTCATCAAGTGTATAGTTTAT
TATAAAGAGCCTTTCTGGAGGAAAAAGGATTACTGTGGAACCATGATTATTGATGGAGAA
GAAGCTCCAGTTGCCTACACGTTGGATGATACCAAACCTGAAGGCAACTATGCTGCCATA
ATGGGATTTATCCTGGCCCACAAAGCCAGAAAACTGGCACGTCTTACCAAAGAGGAAAGG
TTGAAGAAACTTTGTGAACTCTATGCCAAGGTTCTGGGTTCCCTAGAAGCTCTGGAGCCA
GTGCATTATGAAGAAAAGAACTGGTGTGAGGAGCAGTACTCTGGGGGCTGCTACACAACT
TATTTCCCCCCTGGGATCCTGACTCAATATGGAAGGGTTCTACGCCAGCCAGTGGACAGG
ATTTACTTTGCAGGCACCGAGACTGCCACACACTGGAGCGGCTACATGGAGGGGGCTGTA
GAGGCCGGGGAGAGAGCAGCCCGAGAGATCCTGCATGCCATGGGGAAGATTCCAGAGGAT
GAAATCTGGCAGTCAGAACCAGAGTCTGTGGATGTCCCTGCACAGCCCATCACCACCACC
TTTTTGGAGAGACATTTGCCCTCCGTGCCAGGCCTGCTCAGGCTGATTGGATTGACCACC
ATCTTTTCAGCAACGGCTCTTGGCTTCCTGGCCCACAAAAGGGGGCTACTTGTGAGAGTC

# Drug_Target_3_General_Function:
Amino acid transport and metabolism

# Drug_Target_3_General_References:
11049757	Newton-Vinson P, Hubalek F, Edmondson DE: High-level expression of human liver monoamine oxidase B in Pichia pastoris. Protein Expr Purif. 2000 Nov;20(2):334-45.
11753429	Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, Mattevi A: Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol. 2002 Jan;9(1):22-6.
1432104	Zhu QS, Grimsby J, Chen K, Shih JC: Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. J Neurosci. 1992 Nov;12(11):4437-46.
2023912	Grimsby J, Chen K, Wang LJ, Lan NC, Shih JC: Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3637-41.
3387449	Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC: cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4934-8.
8515265	Chen K, Wu HF, Shih JC: The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical. J Neurochem. 1993 Jul;61(1):187-90.

# Drug_Target_3_HGNC_ID:
HGNC:6834

# Drug_Target_3_HPRD_ID:
02401

# Drug_Target_3_ID:
3939

# Drug_Target_3_Locus:
Xp11.23

# Drug_Target_3_Molecular_Weight:
58764

# Drug_Target_3_Name:
Amine oxidase [flavin-containing] B

# Drug_Target_3_Number_of_Residues:
520

# Drug_Target_3_PDB_ID:
2BK3

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01593	Amino_oxidase

# Drug_Target_3_Protein_Sequence:
>Amine oxidase [flavin-containing] B
MSNKCDVVVVGGGISGMAAAKLLHDSGLNVVVLEARDRVGGRTYTLRNQKVKYVDLGGSY
VGPTQNRILRLAKELGLETYKVNEVERLIHHVKGKSYPFRGPFPPVWNPITYLDHNNFWR
TMDDMGREIPSDAPWKAPLAEEWDNMTMKELLDKLCWTESAKQLATLFVNLCVTAETHEV
SALWFLWYVKQCGGTTRIISTTNGGQERKFVGGSGQVSERIMDLLGDRVKLERPVIYIDQ
TRENVLVETLNHEMYEAKYVISAIPPTLGMKIHFNPPLPMMRNQMITRVPLGSVIKCIVY
YKEPFWRKKDYCGTMIIDGEEAPVAYTLDDTKPEGNYAAIMGFILAHKARKLARLTKEER
LKKLCELYAKVLGSLEALEPVHYEEKNWCEEQYSGGCYTTYFPPGILTQYGRVLRQPVDR
IYFAGTETATHWSGYMEGAVEAGERAAREILHAMGKIPEDEIWQSEPESVDVPAQPITTT
FLERHLPSVPGLLRLIGLTTIFSATALGFLAHKRGLLVRV

# Drug_Target_3_Reaction:
RCH2NH2 + H2O + O2 = RCHO + NH3 + H2O2

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine

# Drug_Target_3_SwissProt_ID:
P27338

# Drug_Target_3_SwissProt_Name:
AOFB_HUMAN

# Drug_Target_3_Synonyms:
EC 1.4.3.4
MAO-B
Monoamine oxidase type B

# Drug_Target_3_Theoretical_pI:
7.55

# Drug_Target_3_Transmembrane_Regions:
490-516

#END_DRUGCARD DB02643
